According to SPER Market Research, the Global Antimicrobial Resistance Market (AMR) was valued at USD 10.2 Bn in 2021 and estimated to reach USD 16.4 Bn by 2030 with a CAGR of 5.74%. AMR is a discreetly developing, yet lethal, danger. An expected 750,000 individuals as of now die every year because of drug-resistance infections, and except if earnest move is made, this number will flood throughout the next few years. Simultaneously, 5.7 million individuals die every year from treatable diseases because of an absence of admittance to medication, intensifying the issue as microorganisms are allowed to a greater degree an opportunity to foster obstruction.
Antimicrobial Resistance Market Overview (2022-2032)
- Forecast CAGR (2022-2030): 5.74%
- Forecast Market Size (2030):16.4 billion
Request For Free Sample Report @ https://www.sperresearch.com/report-store/Antibiotic-Resistance-Market.aspx?sample=1
Impact of COVID-19 on the Antimicrobial Resistance Market
Indeed, even in the midst of the continuous COVID-19 pandemic, the pharmaceutical industry has figured out how to convey progress against AMR. One example to be gained from the assorted disappointments and achievements in the battle against COVID-19 is that a particularly intricate worldwide issue must be handled through cooperative, facilitated activity. With attempted and tried strategies and practices in the playbook, the drug business should now speed up its endeavours against this worldwide wellbeing security danger, with help from policymakers and financial backers, and through associations.
Global Antimicrobial Resistance Market Key Segments Covered
The SPER Market Research report seeks to give market dynamics, demand, and supply forecasts for the years up to 2030. This report contains statistics on product type segment growth estimates and forecasts.
By Drug Class:
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Cephalosporins
- Combination therapies
- Others
By Disease Type:
- Carbapenem-resistant Acinetobacter
- Candida auris (C. auris)
- Clostridioides difficile (C. difficile)
- Carbapenem-resistant Enterobacteriaceae (CRE)
- Drug-resistant Neisseria gonorrhoeae (N. gonorrhoeae)
- tuberculosis
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Vancomycin-resistant Enterococci (VRE)
- Others
By Pathogens Type:
- Acinetobacter baumannii (Carbapenem-Resistant)
- Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
- coli/K. pneumoniae (Carbapenem-Resistant)
- Enterococcus faecium (Vancomycin-Resistant)
- Haemophilus Influenzae (Ampicillin-Resistant)
- Pseudomonas aeruginosa (Carbapenem-Resistant)
- Staphylococcus Aureus (Methicillin-Resistant)
- Streptococcus pneumoniae (Penicillin-Non-Susceptible)
- Others
By End-user:
- Hospitals
- Clinics
- Research Organizations
- Others
By Region:
- North America
- Europe
- Asia-Pacific
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends, and strategies for this market. It traces the market's historic and forecast market growth by geography.
Global Antimicrobial Resistance Market Key Players:
The Global Antimicrobial Resistance Market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; Achaogen Inc., Allecra Therapeutics, Basilea Pharmaceutica Ltd., Entasis Therapeutics, Melinta Therapeutics, Nabriva Therapeutics Plc., Paratek Therapeutics, Procarta Biosystems, Seres Therapeutics, Tetraphase Pharmaceuticals, Others.
For More Information, refer to below link:-
Antimicrobial Resistance Market Future Outlook
Related Reports:
Follow Us –
LinkedIn | Instagram | Facebook | Twitter
Contact Us:
Varsha Shrivastav, Business Consultant – U.S.A.
SPER Market Research
+1-347-460-2899
Growth in the market can be attributed to factors such the rising prevalence of infectious diseases; ongoing technological advancements; increasing food safety concerns; and increased funding, research grants, and public-private investments.
Emerging countries and a growing focus on the detection of antimicrobial resistance are expected to provide significant growth opportunities in the market.
What the Market Looks Like?
Predicted to grow at a CAGR of 8.1% during the forecast period, the Global Rapid Microbiology Testing Market is estimated to reach USD 5.09 billion by the end of 2023.
The clinical disease diagnosis application segment is expected to dominate the rapid microbiology testing market during the forecast period.
Based on product, the global market is segmented into instruments, reagents & kits, and consumables.
The ELISpot and FluoroSpot market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2% during the forecast period.
Growth in ELISpot and FluoroSpot market is driven by the rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers.
On the other hand, the availability of alternative detection technologies is expected to limit market growth during the forecast period.“Assay Kits are expected to account for the largest share of the market in 2018” By product type, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products.
The assay kits segment accounted for the largest share in 2018, and this trend is expected to continue during the forecast period.
The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584“Increasing use of ELISpot kits in diagnostic applications in 2018” Based on the applications, the ELISpot and FluoroSpot market is segmented into diagnostic and research applications.
The diagnostics applications segment is further classified into infectious diseases and transplants.
